Sunday, November 30, 2014 7:56:57 AM
1. The author of the service believes that NNVC is a Buy and Hold and as such is holding NNVC personally. He expresses that in a column entitled "Trade Notes" (???).
2. Back in April he recommended to his trading subscribers that they short NNVC and furthermore that is his current advice to them.
That is the way I interpreted your post.
"For Allan Harris' personal account, NNVC is a "buy and hold."
For the traders in his newsletter, it vacillates between short and long depending on current trends."
I fully understand how a person might feel that a stock/company could justify a long term investment with a portion of their investment dollars while at the same time acknowledging that, over that long term, the share price might go up and down.....thereby justifying a separate "trading" investment that could move between long and short positions.
Here's what I don't understand:
Why would someone selling advice buy and hold, and/or recommend the buying and holding of, a stock after having also recommended that their subscribers short that same stock and continuing to recommend shorting that stock for a period of 7 months? Why would someone pay for that clearly confused advice?
If he had advised taking a short position recently instead of back in April, that might be consistent with a two portfolio strategy. As it stands, he's buying and holding a position in shares that he advised his subscribers to short in April, to stay short in, and to continue to short.
"I ated the purple berries"
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM